U.S. markets close in 4 hours 50 minutes

CRISPR Therapeutics AG (CRSP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
51.68-0.55 (-1.05%)
As of 11:09AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Engulfing Line (Bullish)

Engulfing Line (Bullish)

Previous Close52.23
Bid51.49 x 1100
Ask51.63 x 4000
Day's Range50.50 - 53.14
52 Week Range42.51 - 169.76
Avg. Volume1,452,731
Market Cap4.003B
Beta (5Y Monthly)2.01
PE Ratio (TTM)11.00
EPS (TTM)4.70
Earnings DateMay 09, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est121.86
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-9% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for CRSP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CRISPR Therapeutics AG
    Analyst Report: CRISPR Therapeutics AGCRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • Motley Fool

    Why Editas Medicine's Shares Fell 28.9% This Week

    Shares of Editas Medicine (NASDAQ: EDIT), a genome editing biotech company that uses CRISPR/Cas9 and CRISPR/Cas12a genome editing systems to develop therapies, saw its shares plummet 28.9% this week, according to data from S&P Global Market Intelligence. Editas' shares have steadily fallen this year, but it is hardly alone among gene-editing companies. Intellia Therapeutics is down more than 63% so far this year while CRISPR Therapeutics has seen its shares drop more than 38%.

  • Motley Fool

    2 Stocks With 75% to 183% Upside, According to Wall Street

    Let's look at two stocks that boast significant upside potential, going by average price targets set by analysts on the street: Moderna (NASDAQ: MRNA) and CRISPR Therapeutics (NASDAQ: CRSP). Biotech giant Moderna fell along with the broader market in recent months. Moderna currently generates revenue from just one product: its coronavirus vaccine.

  • Investor's Business Daily

    Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis

    Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.